This report provides an overview of global COVID-19 clinical trials, long COVID clinical trials, and trials disrupted by COVID-19.
Scope
- The clinical trials data used for these analyses were extracted from the publisher's Clinical Trials Database. The data was captured in the database as of April 12, 2023. The data was analyzed and segmented by COVID-19 trials, COVID-19 trials for vaccines and therapeutics, and long COVID trials. An analysis was also completed on non-COVID trials impacted due to the pandemic
Reasons to Buy
- Trends of COVID-19 trials through the years
- Comparison of trials by phase, sponsor type and status
- Geographic analysis
- Focus on top sponsors for vaccine and therapeutic trials
- Long COVID analysis
- COVID-19 impact on trials
Table of Contents
- Executive Summary
- Introduction
- Report Scope
- Methodology
- COVID-19 Cases & Deaths Continue but at a Lower Rate
- COVID-19 Clinical Trials Analysis
- COVID-19 Clinical Trials Starts per Month Continue to Decline
- Single-Country COVID-19 Trials Dominate
- Asia-Pacific Continues to Dominate Single-Country Trials
- Europe Still Has the Most Multinational Clinical Trials
- North America Has the Most Clinical Trial Sites
- Slight Change in Order of US States for COVID-19 Sites
- Phase II and Now Completed Trials Dominate the Landscape of COVID-19 Trials
- Primary Endpoints Continue to Be Achieved
- Low Accrual Rate Was the Primary Cause for Trial Termination
- Low Accrual Rate Was the Primary Cause for Trial Termination by Sponsor Type
- COVID-19 Clinical Trials for Vaccines & Therapeutics
- The Amount of Vaccine COVID-19 Clinical Trials Changes Over Time
- Therapeutic COVID-19 Trials Decline More
- Phase II Has Most Trials for Vaccine & Therapeutic COVID-19 Clinical Trials
- Vaccine & Therapeutic COVID-19 Clinical Trials See the Most Trials in Different Trial Statuses
- Sinovac Biotech Still Top Industry Sponsor for Vaccine Trials
- Finlay Vaccine Institute Is the Top Non-industry Vaccine Trial Sponsor
- Sorrento Therapeutics Is Top Industry Sponsor for COVID-19 Therapeutics Trials
- Universities Still Top Non-industry Sponsors
- Long COVID Analysis
- Attention Has Turned to Long COVID
- Majority of Long COVID Trials Are Ongoing
- North America Also Has Most Long COVID Sites
- US and Florida Top Long COVID Sites by Country and State
- A Wide Range of Sponsor Types for Long COVID Trials
- Colchicine Is Top Drug Tested for Long COVID
- Phase II Trial Completions Expected Most in Upcoming Long COVID Events
- Impact of COVID-19 on Clinical Trials
- Clinical Trials Disrupted Due to COVID-19
- Central Nervous System Leads All Therapy Areas in Disrupted Trials
- Where Is the Most Disruption of Clinical Trials?
- Emory University Is Top Sponsor with Most Disruption
- Resumed Clinical Trials Increasing
- Increased Use of Decentralized Clinical Trials
- Central Nervous System Utilizes DCTs the Most
- The Top Industry Sponsor Using DCTs Is GlaxoSmithKline
- University of Oxford and Duke University Top Non-industry Sponsors for DCTs
- Telemedicine Is the Most Used DCT Component
- More Real-World Evidence Used After the Pandemic
- Key Findings
- Appendix
Table 1: Total Number of COVID-19 cases and deaths
List of Figures
Figure 1: Total number of COVID-19 cases and deaths
Figure 2: Number of COVID-19 clinical trials by start date, by month
Figure 3: Number of COVID-19 clinical trials, by multinational versus single-country
Figure 4: Single-country COVID-19 clinical trials, by region and phase
Figure 5: Multinational COVID-19 clinical trials, by region and phase
Figure 6: COVID-19 clinical trial sites, by region
Figures 7 & 8: COVID-19 clinical trial sites, by country and state
Figures 9 & 10: Number of COVID-19 clinical trials, by phase and status
Figure 11: Endpoint status for completed COVID-19 clinical trials
Figure 12: Top reasons for terminated trials, by phase
Figure 13: Top reason for terminated trials, by sponsor type
Figure 14: COVID-19 vaccine clinical trials, by trial start date
Figure 15: COVID-19 therapeutic clinical trials, by trial start date
Figures 16 & 17: Vaccine & therapeutic COVID-19 clinical trials, by phase
Figures 18 & 19: Vaccine & therapeutic COVID-19 clinical trials, by status
Figure 20: Top industry sponsors for COVID-19 vaccine clinical trials
Figure 21: Top non-industry sponsors for COVID-19 vaccine clinical trials
Figure 22: Top industry sponsors for COVID-19 therapeutic clinical trials
Figure 23: Top non-industry sponsors for COVID-19 therapeutic clinical trials
Figure 24: Long COVID clinical trials, by trial start date
Figure 25: Long COVID clinical trials, by trial status
Figure 26: Long COVID clinical trial sites, by region
Figures 27 & 28: Long COVID clinical trial sites, by country and US state
Figure 29: Long COVID clinical trials by sponsor
Figure 30: Long COVID clinical trials by drug
Figure 31: Upcoming long COVID clinical trial events
Figure 32: Clinical trials disrupted due to COVID-19
Figure 33: Disrupted clinical trials, by therapy area
Figures 34 & 35: Disrupted clinical trials activities, by region and country
Figure 36: Disrupted clinical trials, by top sponsors
Figure 37: Resumed clinical trials after being disrupted due to COVID-19, by status
Figure 38: Decentralized clinical trials, by trial start date
Figure 39: Decentralized clinical trials, by therapy area
Figure 40: Top industry sponsors for decentralized clinical trials
Figure 41: Top non-industry sponsors for decentralized clinical trials
Figure 42: Telemedicine clinical trials by trial start year
Figure 43: Number of real-world-evidence trials, by trial end date
